Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

Chau Khuong Joins Catalio Capital Management as General Partner May 25, 2022 03:00PM

Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC Sep 27, 2018 04:46PM

Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC Jun 22, 2018 04:02PM

Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC May 29, 2018 04:14PM

Form 4 ORBIMED ADVISORS LLC For: Apr 30 Filed by: PIERIS PHARMACEUTICALS, INC. May 2, 2018 05:16PM

May 2, 2018 04:58PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Feb 21, 2018 04:47PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Feb 15, 2018 05:02PM Form 4 ORBIMED ADVISORS LLC For: Feb 13 Filed by: PIERIS PHARMACEUTICALS, INC.
Jan 26, 2018 11:51AM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jan 26, 2018 06:04AM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jan 5, 2018 03:15PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jul 12, 2016 02:36PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jul 9, 2015 04:24PM Form SC 13D PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jul 8, 2015 08:00AM Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Mar 25, 2015 05:05PM Pieris Pharmaceuticals Reports Full-Year 2014 Financial Results and Provides Corporate Update

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed